Until the only muscle relaxants available had a long duration of action, the choice was mainly guided by their cardiovascular side effects.


Cirrhotic Patient Plasma Cholinesterase Prolonged Infusion Rocuronium Bromide Liver Diseased Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McCoy EP, Mirakhur RK, Maddineni VR et al (1996) Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth 76:29–33PubMedCrossRefGoogle Scholar
  2. 2.
    Boyd AH, VanMiert MM, Eastwood MB et al (1994) Pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Anaesth 73:P262Google Scholar
  3. 3.
    Shanks CA, Fragen RJ, Ling D (1993) Continuous intravenous infusion of rocuronium (ORG 9426) in patients receiving balanced, enflurane or isoflurane anaesthesia. Anesthesiology 78: 649–651PubMedCrossRefGoogle Scholar
  4. 4.
    Naguib M, Abdulatif M, Al Ghamdi A (1993) Dose response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426) induced neuromuscular blockade. Anesthesiology 79:739–745PubMedCrossRefGoogle Scholar
  5. 5.
    Szenoradszky J, Fisher DM, Segredo V et al (1992) Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology 77:899–904CrossRefGoogle Scholar
  6. 6.
    Cooper RA, Maddineni VR, Mirakhur RK et al (1993) Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (ORG 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 71:222–226PubMedCrossRefGoogle Scholar
  7. 7.
    Khalil M, D’Honneur G, Duvaldestin P et. al. (1994) Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 80:1241–1247PubMedCrossRefGoogle Scholar
  8. 8.
    Magorian T, Wood P, Caldwell J et al (1995) The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 80:754–759PubMedGoogle Scholar
  9. 9.
    Lien CA, Schmith WD, Embree PB et al (1994) The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/ barbiturate anaesthesia. Anesthesiology 80:1296–1302PubMedCrossRefGoogle Scholar
  10. 10.
    Wright PMC, Caldwell JE, Miller RD (1994) Onset and duration of rocuronium and succinylcholine at the adductor pollicis and laryngeal adductor muscles in anaesthetized humans. Anesthesiology 81:1110–1115PubMedCrossRefGoogle Scholar
  11. 11.
    Wierda JMKH, Van Den Broek L, Proost JH et al (1993) Time course of action and endotracheal intubating conditions of ORG 9487, a new short acting steroidal muscle relaxant: a comparison with succinylcholine. Anesth Analg 77:579–584PubMedCrossRefGoogle Scholar
  12. 12.
    De Bros F, Goudsouzian N, Chakravorty S et al (1994) Pharmacokinetic evaluation of the cis cis isomer, alcohol and ester metabolites of mivacurium during prolonged infusions in neurosurgical patients. Anesthesiology 81:A1085CrossRefGoogle Scholar
  13. 13.
    Naguib M, El-Gammal M, Daoud W et al (1995) Human plasma cholinesterase for antagonism of prolonged mivacurium induced neuromuscular blockade. Anesthesiology 83: 1288–1291CrossRefGoogle Scholar
  14. 14.
    Ostergaard D, Jensen FS, Viby-Mogensen J (1995) Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. Anesthesiology 82:1295–1298PubMedCrossRefGoogle Scholar
  15. 15.
    Hart PS, McCarthy GJ, Brown R et al (1995) The effect of plasma cholinesterase activity on mivacurium infusion rates. Anesth Analg 80:760–763PubMedGoogle Scholar
  16. 16.
    Maddineni VR, Mirakhur RK, McCoy EP (1995) Infusion requirements of mivacurium during balanced anaesthesia and anaesthesia supplemented with halothane, isoflurane or enflurane. Anesthesiology 83:A903Google Scholar
  17. 17.
    Devlin JC, Head-Rapson AG, Parker CJR et al (1993) Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 71:227–231PubMedCrossRefGoogle Scholar
  18. 18.
    Bell CF, Hunter JM, Jones RS et al (1985) The use of atracurium and vecuronium in patients with oesophageal varices. Br J Anaesth 57:160–168PubMedCrossRefGoogle Scholar
  19. 19.
    Platt MW, Munday IT, Merrett KL et al (1994) Mivacurium in young adults and elderly patients. Br J Anaesth 73:263PGoogle Scholar
  20. 20.
    Belmont MR, Lien CA, Quessy S et al (1995) The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anaesthesia. Anesthesiology 82: 1139–1146PubMedCrossRefGoogle Scholar
  21. 21.
    Lien CA, Belmont MR, Abalos A et al (1995) The cardiovascular effects and histamine releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anaesthesia. Anesthesiology 82:1131–1138PubMedCrossRefGoogle Scholar
  22. 22.
    Sorooshian SS, Stafford MA, Hull CJ (1994) Pharmacodynamics of 51W89 in young and elderly patients. Br J Anaesth 73:P275Google Scholar
  23. 23.
    Mellinghof H, Diefenbach CH, Buzello W (1991) Neuromuscular and cardiovascular properties of ORG 9426. Anesthesiology 75:A807CrossRefGoogle Scholar
  24. 24.
    Levy JK, Davis GK, Duggan J et al (1994) Determination of the hemodynamics and histamine release of rocuronium (ORG 9426) when administered in increased doses under N20/02-sufentanil anaesthesia. Anesth Analg 78:318–321PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1997

Authors and Affiliations

  • C. Melloni

There are no affiliations available

Personalised recommendations